Digital Content 
NEWS #PharmaBuzz
14 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250610841284/en/U.S.-FDA-Approves-UroGens-ZUSDURI-mitomycin-for-Intravesical-Solution-as-the-First-and-Only-Medication-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC
06 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250606792691/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
02 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250602781070/en/UroGen-Presents-uTRACT-Registry-at-ASCO-2025-Annual-Meeting-Designed-to-Study-Real-World-Use-of-JELMYTO-in-Low-Grade-Upper-Tract-Urothelial-Cancer
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427143523/en/OLYMPUS-Long-Term-Follow-Up-Study-Reports-Nearly-Four-Year-Duration-of-Response-in-Subset-of-Patients-with-Low-Grade-Upper-Tract-Urothelial-Cancer-Who-Achieved-a-Complete-Response-to-Initial-JELMYTO-Treatment
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427131895/en/New-Patient-Reported-Outcomes-from-UGN-102-Clinical-Trials-Show-the-Investigational-Treatment-Did-Not-Adversely-Affect-Functionality-Symptom-Burden-and-Quality-of-Life-in-Patients-with-LG-IR-NMIBC
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427607639/en/New-Long-Term-Follow-Up-Data-from-OPTIMA-II-Study-of-UGN-102-Demonstrates-Median-Duration-of-Response-of-Two-Years-in-Patients-with-LG-IR-NMIBC
Share 